{"transactions":[{"id":2538580,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2021-10-20T20:09:01.000Z","date":"2021-10-18","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in 12 equal monthly installments beginning on July 1, 2021, subject to Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date."}],"balance_after":225000,"derivative":{"exercise_price":1.39,"expiration_date":"2031-10-18","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000899243-21-040746","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321040746/doc4.xml","form_type":"4"}},{"id":2559415,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-09-28T01:26:38.000Z","date":"2021-09-23","kind":"exercise","acquired":false,"shares":266668,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the \"Warrants\") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), pursuant to which twice as many shares could be purchased for double the total original exercise price."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2021-09-23","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":266668},"source":{"system":"sec-edgar","filing":"0000899243-21-037904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321037904/doc4.xml","form_type":"4"}},{"id":2559414,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-09-28T01:26:38.000Z","date":"2021-09-23","kind":"exercise","acquired":false,"shares":133332,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the \"Warrants\") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), pursuant to which twice as many shares could be purchased for double the total original exercise price."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2021-09-23","expiration_date":"2022-07-26","underlying":"Common Stock","underlying_shares":133332},"source":{"system":"sec-edgar","filing":"0000899243-21-037904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321037904/doc4.xml","form_type":"4"}},{"id":2559413,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-09-28T01:26:38.000Z","date":"2021-09-23","kind":"exercise","acquired":false,"shares":888888,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the \"Warrants\") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), pursuant to which twice as many shares could be purchased for double the total original exercise price."}],"balance_after":0,"derivative":{"exercise_price":0.45,"exercise_date":"2021-09-23","expiration_date":"2024-12-13","underlying":"Common Stock","underlying_shares":888888},"source":{"system":"sec-edgar","filing":"0000899243-21-037904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321037904/doc4.xml","form_type":"4"}},{"id":2559412,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-09-28T01:26:38.000Z","date":"2021-09-23","kind":"grant","acquired":true,"shares":266668,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the \"Warrants\") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), pursuant to which twice as many shares could be purchased for double the total original exercise price."}],"balance_after":266668,"derivative":{"exercise_price":0.75,"exercise_date":"2021-09-23","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":266668},"source":{"system":"sec-edgar","filing":"0000899243-21-037904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321037904/doc4.xml","form_type":"4"}},{"id":2559411,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-09-28T01:26:38.000Z","date":"2021-09-23","kind":"grant","acquired":true,"shares":133332,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the \"Warrants\") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), pursuant to which twice as many shares could be purchased for double the total original exercise price."}],"balance_after":133332,"derivative":{"exercise_price":0.75,"exercise_date":"2021-09-23","expiration_date":"2022-07-26","underlying":"Common Stock","underlying_shares":133332},"source":{"system":"sec-edgar","filing":"0000899243-21-037904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321037904/doc4.xml","form_type":"4"}},{"id":2559410,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-09-28T01:26:38.000Z","date":"2021-09-23","kind":"grant","acquired":true,"shares":888888,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the \"Warrants\") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), pursuant to which twice as many shares could be purchased for double the total original exercise price."}],"balance_after":888888,"derivative":{"exercise_price":0.45,"exercise_date":"2021-09-23","expiration_date":"2024-12-13","underlying":"Common Stock","underlying_shares":888888},"source":{"system":"sec-edgar","filing":"0000899243-21-037904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321037904/doc4.xml","form_type":"4"}},{"id":2559409,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-09-28T01:26:38.000Z","date":"2021-09-23","kind":"disposition_to_issuer","acquired":false,"shares":133334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the \"Warrants\") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), pursuant to which twice as many shares could be purchased for double the total original exercise price."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":133334},"source":{"system":"sec-edgar","filing":"0000899243-21-037904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321037904/doc4.xml","form_type":"4"}},{"id":2559408,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-09-28T01:26:38.000Z","date":"2021-09-23","kind":"disposition_to_issuer","acquired":false,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the \"Warrants\") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), pursuant to which twice as many shares could be purchased for double the total original exercise price."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2017-07-26","expiration_date":"2022-07-26","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0000899243-21-037904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321037904/doc4.xml","form_type":"4"}},{"id":2559407,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2021-09-28T01:26:38.000Z","date":"2021-09-23","kind":"disposition_to_issuer","acquired":false,"shares":444444,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2021, as an inducement to exercise, the Issuer and the Reporting Person agreed to amend three warrants held by the Reporting Person (the \"Warrants\") to purchase a total of 644,444 shares of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), pursuant to which twice as many shares could be purchased for double the total original exercise price."}],"balance_after":0,"derivative":{"exercise_price":0.45,"exercise_date":"2019-12-13","expiration_date":"2024-12-13","underlying":"Common Stock","underlying_shares":444444},"source":{"system":"sec-edgar","filing":"0000899243-21-037904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321037904/doc4.xml","form_type":"4"}},{"id":2559406,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-28T01:26:38.000Z","date":"2021-09-23","kind":"exercise","acquired":true,"shares":266668,"price":0.75,"value":200001.0,"ownership":{"direct":true},"balance_after":7990211,"source":{"system":"sec-edgar","filing":"0000899243-21-037904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321037904/doc4.xml","form_type":"4"}},{"id":2559405,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-28T01:26:38.000Z","date":"2021-09-23","kind":"exercise","acquired":true,"shares":133332,"price":0.75,"value":99999.0,"ownership":{"direct":true},"balance_after":7723543,"source":{"system":"sec-edgar","filing":"0000899243-21-037904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321037904/doc4.xml","form_type":"4"}},{"id":2559404,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-28T01:26:38.000Z","date":"2021-09-23","kind":"exercise","acquired":true,"shares":888888,"price":0.45,"value":399999.6,"ownership":{"direct":true},"balance_after":7590211,"source":{"system":"sec-edgar","filing":"0000899243-21-037904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321037904/doc4.xml","form_type":"4"}},{"id":2743712,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-04-21T22:27:38.000Z","date":"2021-04-19","kind":"other","acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.35,"exercise_date":"2016-05-10","expiration_date":"2021-05-10","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001807094-21-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709421000003/primary_doc.xml","form_type":"4"}},{"id":2743711,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-21T22:27:38.000Z","date":"2021-04-19","kind":"other","acquired":true,"shares":250000,"price":1.35,"value":337500.0,"ownership":{"direct":true},"balance_after":6701323,"source":{"system":"sec-edgar","filing":"0001807094-21-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709421000003/primary_doc.xml","form_type":"4"}},{"id":2996063,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-04T02:09:17.000Z","date":"2020-11-02","kind":"purchase","acquired":true,"shares":193500,"price":2.57,"value":497295.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $2.50 to $2.61. The price above reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected"}],"balance_after":6451323,"source":{"system":"sec-edgar","filing":"0001807094-20-000026","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000026/primary_doc.xml","form_type":"4"}},{"id":3000324,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-26T23:45:20.000Z","date":"2020-10-23","kind":"purchase","acquired":true,"shares":120000,"price":2.4859,"value":298308.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $2.4701 to $2.49. The price reported reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":6257823,"source":{"system":"sec-edgar","filing":"0001807094-20-000024","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000024/primary_doc.xml","form_type":"4"}},{"id":3099482,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2020-06-27T01:39:43.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"56,250 shares vest on August 31, 2020; the balance vests in equal amounts on November 30, 2020, February 28, 2021 and May 31, 2021, subject to amendment to the equity incentive plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This Form 4 amends the expiration date of the option incorrectly reported on the original Form 4 filed with the SEC on June 26, 2020."}],"balance_after":225000,"derivative":{"exercise_price":6.15,"expiration_date":"2030-06-25","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001807094-20-000011","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000011/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-06-26"}},{"id":3099480,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock","published_at":"2020-06-27T01:19:31.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"56,250 shares vest on August 31, 2020. The balance vests in equal amounts on November 30, 2020, February 28, 2021 and May 31, 2021, subject to amendment to the equity incentive plan."}],"balance_after":225000,"derivative":{"exercise_price":6.15,"expiration_date":"2020-06-25","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001807094-20-000009","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000009/primary_doc.xml","form_type":"4"}},{"id":3333309,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-24T00:06:38.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":750000,"derivative":{"exercise_price":0.63,"exercise_date":"2019-12-19","expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0000899243-19-030000","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319030000/doc4.xml","form_type":"4"}},{"id":3340253,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2019-12-17T21:32:57.000Z","date":"2019-12-13","kind":"grant","acquired":true,"shares":625000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.30 per share of common stock and related warrants."}],"balance_after":625000,"derivative":{"exercise_price":0.45,"exercise_date":"2019-12-13","expiration_date":"2024-12-13","underlying":"Common Stock","underlying_shares":625000},"source":{"system":"sec-edgar","filing":"0000899243-19-029421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319029421/doc4.xml","form_type":"4"}},{"id":3340252,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-17T21:32:57.000Z","date":"2019-12-13","kind":"grant","acquired":true,"shares":833333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.30 per share of common stock and related warrants."}],"balance_after":6137823,"source":{"system":"sec-edgar","filing":"0000899243-19-029421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319029421/doc4.xml","form_type":"4"}},{"id":3485445,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2019-06-20T01:05:49.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in four equal quarterly installments, commencing on September 1, 2019."}],"balance_after":100000,"derivative":{"exercise_price":0.52,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-19-017516","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017516/doc4.xml","form_type":"4"}},{"id":3760381,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:03:11.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":250000,"derivative":{"exercise_price":1.35,"exercise_date":"2016-05-10","expiration_date":"2021-05-10","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-18-029260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029260/doc4.xml","form_type":"4"}},{"id":3760380,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:03:11.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":66666,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2022-07-26","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0000899243-18-029260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029260/doc4.xml","form_type":"4"}},{"id":3760379,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:03:11.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":133334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":133334,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":133334},"source":{"system":"sec-edgar","filing":"0000899243-18-029260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029260/doc4.xml","form_type":"4"}},{"id":3760378,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:11.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options (including predecessor options) vest in four equal quarterly installments commencing on September 1, 2018."}],"balance_after":100000,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029260/doc4.xml","form_type":"4"}},{"id":3760377,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:11.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":0.8,"exercise_date":"2018-02-15","expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029260/doc4.xml","form_type":"4"}},{"id":3760376,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:11.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":96397,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":96397,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":96397},"source":{"system":"sec-edgar","filing":"0000899243-18-029260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029260/doc4.xml","form_type":"4"}},{"id":3760375,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:11.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":75000,"derivative":{"exercise_price":0.57,"exercise_date":"2018-09-01","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-18-029260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029260/doc4.xml","form_type":"4"}},{"id":3760374,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:11.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":1.09,"exercise_date":"2017-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029260/doc4.xml","form_type":"4"}},{"id":3760373,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:11.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":0.975,"exercise_date":"2016-09-01","expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029260/doc4.xml","form_type":"4"}},{"id":3760372,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:11.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":25000,"derivative":{"exercise_price":1.55,"exercise_date":"2013-06-01","expiration_date":"2022-06-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-029260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029260/doc4.xml","form_type":"4"}},{"id":3760371,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:11.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":2,"exercise_date":"2012-08-08","expiration_date":"2021-08-08","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029260/doc4.xml","form_type":"4"}},{"id":3760370,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:03:11.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":0.66,"exercise_date":"2015-06-01","expiration_date":"2019-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029260/doc4.xml","form_type":"4"}},{"id":3760369,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-19T13:03:11.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":5304490,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":5304490,"source":{"system":"sec-edgar","filing":"0000899243-18-029260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029260/doc4.xml","form_type":"4"}},{"id":3762626,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":1.35,"exercise_date":"2016-05-10","expiration_date":"2021-05-10","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-18-029183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029183/doc4.xml","form_type":"4"}},{"id":3762625,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2022-07-26","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0000899243-18-029183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029183/doc4.xml","form_type":"4"}},{"id":3762624,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":133334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":133334},"source":{"system":"sec-edgar","filing":"0000899243-18-029183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029183/doc4.xml","form_type":"4"}},{"id":3762623,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in four equal quarterly installments commencing on September 1, 2018."}],"balance_after":0,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029183/doc4.xml","form_type":"4"}},{"id":3762622,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.8,"exercise_date":"2018-02-15","expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029183/doc4.xml","form_type":"4"}},{"id":3762621,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":96397,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":96397},"source":{"system":"sec-edgar","filing":"0000899243-18-029183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029183/doc4.xml","form_type":"4"}},{"id":3762620,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.57,"exercise_date":"2018-09-01","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-18-029183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029183/doc4.xml","form_type":"4"}},{"id":3762619,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":1.09,"exercise_date":"2017-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029183/doc4.xml","form_type":"4"}},{"id":3762618,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.975,"exercise_date":"2016-09-01","expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029183/doc4.xml","form_type":"4"}},{"id":3762617,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":1.55,"exercise_date":"2013-06-01","expiration_date":"2022-06-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-029183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029183/doc4.xml","form_type":"4"}},{"id":3762616,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":2,"exercise_date":"2012-08-08","expiration_date":"2021-08-08","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029183/doc4.xml","form_type":"4"}},{"id":3762615,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.66,"exercise_date":"2015-06-01","expiration_date":"2019-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029183/doc4.xml","form_type":"4"}},{"id":3762614,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T23:25:21.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":5304490,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029183/doc4.xml","form_type":"4"}},{"id":3822886,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-09-07T22:22:10.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The two transactions reported in Table II above involved the amendment of an outstanding warrant to reduce the exercise price from $1 per share to $0.75 per share. The amendment is reported above as the cancellation of the \"old\" warrant and the acquisition of a new one."}],"balance_after":66666,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2022-07-26","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0000899243-18-024028","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318024028/doc4.xml","form_type":"4"}},{"id":3822885,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-09-07T22:22:10.000Z","date":"2018-01-31","kind":"disposition_to_issuer","acquired":false,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The two transactions reported in Table II above involved the amendment of an outstanding warrant to reduce the exercise price from $1 per share to $0.75 per share. The amendment is reported above as the cancellation of the \"old\" warrant and the acquisition of a new one."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2017-07-26","expiration_date":"2022-07-26","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0000899243-18-024028","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318024028/doc4.xml","form_type":"4"}},{"id":3897808,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-06-12T21:53:05.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in four equal quarterly installments commencing on September 1, 2018."}],"balance_after":100000,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-016225","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318016225/doc4.xml","form_type":"4"}},{"id":4053923,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-02-16T23:03:19.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":0.8,"exercise_date":"2018-02-15","expiration_date":"2023-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-004436","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318004436/doc4.xml","form_type":"4"}},{"id":4053922,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-02-16T23:03:19.000Z","date":"2018-02-15","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such options were fully vested and exercisable as of the date of the reported transactions."}],"balance_after":0,"derivative":{"exercise_price":0.8,"expiration_date":"2018-06-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-004436","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318004436/doc4.xml","form_type":"4"}},{"id":4069679,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-02-10T01:04:13.000Z","date":"2018-02-07","kind":"grant","acquired":true,"shares":96397,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 7, 2018, the board of directors of CytoDyn Inc. approved an amendment to its director compensation program, providing for payment in stock options, in lieu of cash, of all unpaid director retainer fees for the four-quarter period ending February 28, 2018. The number of options awarded to each director was determined by applying a price of $0.31 per option, which was the fair value estimate of the option award as of the grant date, using the Black-Scholes option pricing model."}],"balance_after":96397,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":96397},"source":{"system":"sec-edgar","filing":"0000899243-18-003457","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318003457/doc4.xml","form_type":"4"}},{"id":4080906,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-02-03T01:19:09.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":133334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.50 per share of common stock and related warrants."}],"balance_after":133334,"derivative":{"exercise_price":0.75,"exercise_date":"2018-01-31","expiration_date":"2023-01-31","underlying":"Common Stock","underlying_shares":133334},"source":{"system":"sec-edgar","filing":"0000899243-18-002768","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318002768/doc4.xml","form_type":"4"}},{"id":4080905,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-03T01:19:09.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":207248,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased together, as part of a registered direct offering, at a combined price of $0.50 per share of common stock and related warrants."}],"balance_after":5304490,"source":{"system":"sec-edgar","filing":"0000899243-18-002768","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318002768/doc4.xml","form_type":"4"}},{"id":4249796,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2017-07-28T20:07:07.000Z","date":"2017-07-26","kind":"grant","acquired":true,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Subject to adjustment in the event of certain stock split or reverse stock split recapitalizations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of a private offering to accredited investors, the reporting person purchased from the issuer for a combined price of $100 thousand (i) a $100 thousand convertible promissory note, bearing interest at 7.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.75 per share, and (ii) a warrant covering 50% of the number of shares underlying the convertible promissory note, at an exercise price of $1.00 per share."}],"balance_after":66666,"derivative":{"exercise_price":1,"exercise_date":"2017-07-26","expiration_date":"2022-07-26","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0000899243-17-019283","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317019283/doc4.xml","form_type":"4"}},{"id":4249795,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Promissory Note","published_at":"2017-07-28T20:07:07.000Z","date":"2017-07-26","kind":"grant","acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Subject to adjustment in the event of certain stock split or reverse stock split recapitalizations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of a private offering to accredited investors, the reporting person purchased from the issuer for a combined price of $100 thousand (i) a $100 thousand convertible promissory note, bearing interest at 7.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.75 per share, and (ii) a warrant covering 50% of the number of shares underlying the convertible promissory note, at an exercise price of $1.00 per share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Does not include additional shares issuable upon conversion of accrued interest."}],"balance_after":100000,"derivative":{"exercise_price":0.75,"exercise_date":"2017-07-26","expiration_date":"2018-01-31","underlying":"Common Stock","underlying_shares":133333},"source":{"system":"sec-edgar","filing":"0000899243-17-019283","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317019283/doc4.xml","form_type":"4"}},{"id":4294824,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":134419,"kind":"person","name":"Naydenov Jordan G","position":1,"cik":"0001469618","reported_name":"Naydenov Jordan G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2017-06-05T20:46:23.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to stockholder approval, at the next annual meeting, of the increase in the number of shares of common stock authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, the options will vest in four equal quarterly installments commencing on September 1, 2017."}],"balance_after":75000,"derivative":{"exercise_price":0.57,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-17-015354","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924317015354/doc4.xml","form_type":"4"}}]}